Biogen CEO Says Alzheimer's Uptake 'Is Delayed,' But Shares Pop On Earnings Beat

Biogen CEO Says Alzheimer's Uptake 'Is Delayed,' But Shares Pop On Earnings Beat

Source: 
Investors Business Daily
snippet: 

Biogen stock jumped early Wednesday after the biotech company reported adjusted income of $4.77 per share on $2.78 billion in third-quarter sales.

On average, analysts polled by FactSet expected Biogen (BIIB) to earn $4.11 per share on $2.67 billion in sales.

Biogen also reported $300,000 in sales of its new Alzheimer's drug, Aduhelm. Chief Executive Michel Vounatsos said uptake is delayed "but we continue to believe in its long-term potential."